Citations

Clear

415 citation(s) found for "Black, DF".

Dermatomyositis: a comparison of clinical and histopathologic findings in Black and White patients
Wondimu, Bitania , Sluzevich, Jason C. , Sokumbi, Olayemi , Sluzevich, Jason C , Sokumbi, Olayemi

Mayo Clinic

International Journal of Dermatology | December 11, 2024 | Volume: 64 | Issue: 6 | Pages: 1139-1140

10.1111/ijd.17609 | PMID 39660353 Get It

Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
Negaard, Brianna J, Chartier, Loïc , Guerra, Luca, Haddadi, Sara , Black, Harrison, Trevis, Thomas , Tong, Tsz Hung, Moalem, Kamilia , Johnston, Anna , Hampel, Paul J. , Johnson, Jeffrey S. , Elizabeth, Steinepreis, Yang, Pinguang, Kosciejew, Serena, Elizabeth, Gould, Manos, Kate , Nowakowski, Grzegorz S. , Hodges, Georgina, Flowers, Christopher R. , Lossos, Izidore S. , Ansell, Stephen M., Mondello, Patrizia , Gysbers, Brianna J. , Arcaini, Luca , Tobin, Joshua W.D. , Link, Brian K. , Feldman, Andrew L. , Chihara, Dai , Casulo, Carla , Cottereau, Anne-Ségolène , Olson, Joshua, Romancik, Jason T. , Black, Harrison, Mou, Eric , Cheah, Chan Y. , Salvaris, Ross , Habermann, Thomas M. , Martin, Peter, Kahl, Brad S. , Nastoupil, Loretta J. , Talaulikar, Dipti , Trotman, Judith , Cerhan, James R. , Burack, Richard , Luminari, Stefano , Morschhauser, Franck , Ansell, Stephen M. , Maurer, Matthew J.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3007-3007

10.1182/blood-2024-202088 Get It

Background: Positron emission tomography (PET) scan is the imaging modality of choice for initial staging and response assessment of follicular lymphoma (FL). Quantitative parameters such as standardized uptake value (SUV) have been investigated as putative prognosticators in FL, with high baseline SUVmax predicting aggressive disease. To date, there is no data to guide treatment choices in patients (pts) with high SUVmax but with no documented evidence of histologic transformation (HT). Specifically, it remains unclear whether anthracycline-containing regimens, such as R-CHOP, are more beneficial than R-Bendamustine (BR) in these pts. Therefore, we aimed to compare the efficacy of frontline R-CHOP and BR in newly diagnosed FL pts based on the SUVmax at baseline PET (bPET). Patients and Methods: Pts with newly diagnosed, biopsy-proven FL1-2 and FL3A who had a bPET scan and who received either first-line R-CHOP or BR within 6 months of diagnosis between 2002 and 2022 were evaluated. Analysis was restricted to pts with age < 70 years to reduce confounding of age with treatment selection. Cohorts included were the FOLL12 (n=562, Luminari et al JCO 2022) and the R-chemotherapy arm of the RELEVANCE (n=216, Morschhauser et al NEJM 2018) clinical trials, the prospectively enrolled Molecular Epidemiology Resource (MER) and the Lymphoma Epidemiology of Outcomes (LEO) cohorts (n=288) and a retrospective cohort from 13 Australian centers (n=219). Choice of chemotherapy regimen was per treating physician. Maintenance was per protocol (FOLL12/RELEVANCE) or per treating physician (MER/LEO/Australia). Event-free survival (EFS) and overall survival (OS) were defined as time from treatment initiation to progression, relapse, retreatment or death; both were censored at 72 months due to varying follow-up across cohorts. SUVmax was grouped by tertile within each cohort to account for potential differences in SUVmax distributions and patient populations across cohorts. Kaplan Meier curves and multivariable Cox models cohort-stratified and adjusted for clinical factors (FLIPI, ECOG PS, age, grade 3A) were used to evaluate outcomes. Results: The median age at diagnosis was 57 years (IQR 49-64). 651 (51%) pts were treated with R-CHOP and 634 (49%) with BR. Within the study cohorts, there was a prevalence of cases receiving BR compared to R-CHOP in the Australian (90% vs 10%) and MER/LEO (68% vs 32%) cohorts, while the opposite was observed in the RELEVANCE (16% vs 84%) and FOLL12 (37% vs 63; p<0.001) trials. Pts receiving R-CHOP were slightly younger (median 56 vs 58 years, p=0.005), more frequently had grade 3A (17% vs 7%, p<0.001), elevated LDH (27% vs 22%, p=0.029), bulky disease > 7 cm (44% vs 37%, p=0.019), lower ECOG PS (PS >1 7% vs 13%, p<0.001), and higher rate of high risk FLIPI (37% vs 30%, p=0.005). Baseline SUVmax was slightly lower in R-CHOP (median 10.7, IQR 7.9-14.9) vs BR (median 11.0, IQR 8.2-14.2) treated pts (p=0.0045). At a median follow-up of 56 months (range, 1-72 months), 415 pts (32%) had an event and 103 (8%) died. Higher SUVmax was not associated with EFS (middle tertile HR=0.96, 95% CI 0.76-1.22; upper tertile HR=0.86, 95% CI 0.68-1.09; p=0.45) or OS (middle tertile HR=1.28, 95% CI 0.80-2.05; upper tertile HR=0.97, 95% CI 0.59-1.59; p=0.44) in multivariable models stratified on cohort and adjusted for treatment and clinical factors. We then compared outcomes by treatment within tertiles of SUVmax. In multivariable models, R-CHOP had modestly inferior EFS to BR in low (HR=1.27, 95% CI 0.84-1.93) and middle tertiles (HR=1.49, 95% CI 0.99-2.25), and modestly superior OS to BR in low (HR=0.59, 95% CI 0.23-1.47) and middle (HR=0.79, 95% CI 0.37-1.71) tertiles. Both EFS (HR=1.06, 95% CI 0.71-1.58) and OS (HR=1.02, 95% CI 0.45-2.30) for R-CHOP were similar to BR in the highest tertile. No comparisons identified a statistically significant benefit for either therapy in multivariable models when evaluating SUVmax tertile subsets. Conclusions: In this large multicenter study of newly diagnosed FL pts with bPET who received frontline immunochemotherapy, higher baseline SUVmax was not associated with inferior outcomes after adjusting for treatment and clinical factors. Within the caveats of retrospective studies and confounding of treatment selection, these data provide no clear insights for SUVmax-based therapy selection in first-line follicular lymphoma pts treated with immunochemotherapy.
Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar
Kambhampati, Swetha , Nabhan, Chadi , Knopf, Kevin , Martin, Linda W. , Carson, Kenneth R. , Watson, Gretchen, Smith, Edward , Zyszkowski, Edward, Jacob, Sony, Banegas, Dennis, Hrushesky, William J.M. , Macdougall, Iain C. , Gonzalez-Brio, Manuel, Sartor, Oliver, Gale, Robert Peter, Bennett, Charles L. , Thiruvengadam, Nikhil Ravi , Rosen, Steven T. , Martin, Linda, Georgantopoulos, Peter , Banegas, Dennis, Aboulafia, David M.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3638-3638

10.1182/blood-2024-206590 Get It

Background: Two National Cancer Institute-funded pharmacovigilance programs have identified 49 serious hematology-related ADRs since 1998. The programs, called RADAR (Research on Adverse Drug events and Reports) and then SONAR (Southern Network on Adverse Reactions) involve > 50 institutions and > 75 co-investigators worldwide. The work builds on three prior studies evaluating “Davids and Goliaths” in medical oncology and in cardiology (PLOS One, eClinicalMedicine, and Journal of Scientific and Professional Integrity). Here we review the hematology focused safety investigations of RADAR/SONAR. Methods: Data were based on initial safety signals being identified by a RADAR/SONAR co-investigator. Then, case-series were derived. Collaborations with basic scientists allowed for basic science correlative studies. Results were disseminated primarily as Brief Report in the literature and Black Box warnings on the related drug. In some instances, studies identified hematologic toxicities that prevent FDA from approving a submitted drug application. Results: sADRs were frequently identified based on very small case series, including ticlopidine-and clopidogrel associated thrombotic thrombocytopenic purpura (22 and 10 patients, respectively), thalidomide- and lenalidomide-associated venous thromboembolism (9 and 5 patients, respectively), rituximab-associated progressive multi-focal leukoencephalopathy (22 patients), peginesatide-associated fatal anaphylaxis (5 patients), and COVID-19 vaccine associated immune thrombocytopenia (1 patient). Meta-analyses provided data for epoetin- and darbepoetin-associated mortality among cancer patients and lenalidomide- and thalidomide-associated venous thromboembolism. Following the onset of the COVID-19 pandemic, RADAR/SONAR investigated social media and pre-prints (COVID-19 vaccine associated cerebral vein thrombosis and immune thrombocytopenia). Time from FDA approval to sADR discovery was a median of 5 years (range, 0 months (thalidomide-associated venous thromboembolism) to 34 years (ciprofloxacin-associated neuropsychiatric toxicity). Basic science correlative studies identified ADAMTS13 autoantibodies (ticlopidine), leachates that developed in a multi-dose vial (peginesatide), anti-red blood cell antibodies (epoetin-associated pure red cell aplasia), and high-risk genes (fluoroquinolones and rituximab). Overall, RADAR/SONAR studies are estimated to have saved over 1 million lives and also resulted in overall payments to the Department of Justice of $1.5 billion (related to marketing of unsafe drugs). Discussion: RADAR/SONAR has proven to be a very important adjunct to FDA and pharmaceutical manufacturer-led safety investigations for hematology, paralleling the success in medical oncology and in cardiology. Going forward, independent centers of excellence for safety-focused investigations such as the CERSI network and the SENTINEL network (both are NIH funded) should be broadened to include a hematology-focused safety center.
Decentralized Clinical Trials at Home: Commentary on Caregivers’ Burden
Bolajoko, Opeyemi , Fullwood, Dottington , Colissa, Mahin, Merriweather, Arnold, Merriweather, Callie, Odedina, Folakemi T., Bolajoko, Opeyemi

Mayo Clinic

Cancer Control | December 5, 2024 | Volume: 31 | Issue: No issue available | Pages: No page available

10.1177/10732748241305581 | PMID 39638309 Get It

Decentralized clinical trials (DCTs) provide the opportunity to bring interventional studies closer to participants in their homes or a suitable location closer to prospective participants, thus increasing participants’ diversity, accrual, retention, health care, and research access. However, little is known about the burden of caring for cancer patients participating in DCTs. This article describes how DCTs might affect the caregivers of cancer patients. The points discussed include how technological challenges for those without adequate digital literacy can overburden participants and their caregivers at home, as well as managing and optimizing research logistics and safe handling of samples. In addition, the shift in labor from the study personnel to the participants and their caregivers in a bid to complete several study procedures on their own can increase the care burden, especially if not well incentivized. Therefore, it is important to accumulate evidence on ways to optimize DCTs, especially in the home environment, without increasing the burden on caregivers, who will be an integral part of the study team and support the research at home.
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)
Chertkow, Howard , Rockwood, Kenneth, Bartha, Robert , Beaudoin, Camille, Bélanger, Nathalie , Bellec, Pierre , Belleville, Sylvie, Bergman, Howard , Best, Sarah, Bherer, Louis , Borrie, Michael, Camicioli, Richard , Chan, Senny , Crowshoe, Lynden , Cynader, Max S., Das, Samir , Dixon, Roger A., Ducharme, Simon , Fahnestock, Margaret , Feldman, Howard , Ferland, Guylaine , Fogarty, Jennifer, Gauthier, Serge, Greenwood, Carol E., Henri-Bellemare, Charlie, Herrmann, Nathan, Itzhak, Inbal, Jacklin, Kristen , Mackenzie, Ian R. , Masellis, Mario, Maxwell, Colleen J. , McLaurin, JoAnne, Mohades, Zia, Montero‐Odasso, Manuel , Morgan, Debra, Nygaard, Haakon B. , O’Connell, Megan E. , Petersen, Ron, Pilon, Randi, Rajah, Maria Natasha, Rapoport, Mark , Roach, Pamela, Robillard, Julie M. , Rylett, R. Jane , Sadavoy, Joel , Seitz, Dallas , Walker, Jennifer , Whitehead, Victor, Wittich, Walter , Feldman, Howard H , Phillips, Natalie A. , Rockwood, Kenneth J. , Anderson, Nicole D. , Andrew, Melissa Kathryn , Bélanger, Nathalie, Belleville, Sylvie , Bethell, Jennifer , Black, Sandra E. , Carrier, Julie C , Cashman, Neil R. , Cuello, A. Claudio , Dang‐Vu, Thien Thanh , Einstein, Gillian , Evans, Alan Charles , Finger, Elizabeth C. , Fisk, John D. , Fon, Edward A , Gan‐Or, Ziv , Hogan, David B. , Hsiung, Ging‐Yuek Robin , Lanctôt, Krista L. , Lim, Andrew S. P. , McAiney, Carrie A. , McGilton, Katherine S. , McLaurin, JoAnne , Mihailidis, Alex , Morgan, Debra, Naglie, Gary , Rajah, Maria Natasha , Rogaeva, Ekaterina A. , Rosa-Neto, Pedro , George‐Hyslop, Peter St , Smith, Eric Edward , Stefanovic, Bojana , Vedel, Isabelle , Wellington, Cheryl L.

Mayo Clinic

Journal of Alzheimer’s Disease | December 5, 2024 | Volume: 102 | Issue: 3 | Pages: 535-561

10.1177/13872877241290990 | PMID 39636028 Get It

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014–2019; 2019–2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019–2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized “centrally-organized” approach to dementia research can catalyze important progress nationally and yield significant and measurable results.
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
Fatola, Ayotola , Evans, Michael D. , Brown, Jenna , Davis, Elizabeth E. , Johnson, Andrew D. , Antun, Ana G., Farland, Andrew M., Metjian, Ara , Park, Yara A. , Ridder, Gustaaf de, Gibson, Briana, Eubanks, Susan, Akwaa, Frank, Clover, Todd, Sadler, J. Evan, Upreti, Harsh Vardhan , Kocher, Nicole K. , Gangaraju, Radhika , Masias, Camila , Mazepa, Marshall , Metjian, Ara , Kasthuri, Raj S , Baumann Kreuziger, Lisa , Sridharan, Meera , McCrae, Keith R , Lim, Ming Y , Zheng, X Long , Raval, Jay S , Cataland, Spero R , Mazepa, Marshall A , Evans, Michael D , Davis, Elizabeth, Woods, Ryan, Kasthuri, Raj S. , Liles, Darla , Kreuziger, Lisa Baumann , Sridharan, Meera , Go, Ronald S. , McCrae, Keith R. , Zheng, X. Long , Raval, Jay S. , Cataland, Spero R. , Chaturvedi, Shruti

Mayo Clinic

Blood Advances | December 3, 2024 | Volume: 9 | Issue: 2 | Pages: 417-424

10.1182/bloodadvances.2024013313 | PMID 39626301 Get It

Abstract Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect is maintained with subsequent treatment courses has not been studied. Using the United States Thrombotic Microangiopathy Consortium (USTMA) retrospective iTTP registry, we evaluated clinical relapse-free survival (RFS) with subsequent courses of rituximab treatment in multiply relapsing patients. Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P = .04). White patients’ clinical relapse risk after the second and subsequent rituximab courses was not significantly different compared with the first (hazard ratio [HR], 1.86; 95% confidence interval [CI], 0.22-15.80; P = .57), whereas for Black patients, clinical relapse risk was significantly higher after the second or subsequent courses (HR, 2.82; 95% CI, 1.52-5.24; P = .001). In the prospective cohort, overall RFS progressively shortened after each episode of rituximab treatment with the first episode having the longest RFS (2.8 years; interquartile range, 2.0-6.0) and this loss of response durability was most pronounced in Black patients. The durability of rituximab’s effect declines with subsequent treatments, which is more pronounced in Black patients, who may benefit from closer monitoring and alternative immunomodulatory approaches such as maintenance rituximab and consideration of other agents.
From Unheard to Empowered: Utilizing Communication Accommodation Theory to Address Black Men’s With Prostate Cancer Healthcare Preferences
Fullwood, Dottington , Bolajoko, Opeyemi , Gunderson, Justine, Ramirez-Rivera, Caleb O. , Pressey, Shannon, Nosbush, Kelly, Young, Mary Ellen , Asiedu, Gladys B. , Fallon, Elizabeth, Bolajoko, Opeyemi , Ramirez-Rivera, Caleb O , Young, Mary Ellen , Krieger, Janice, Asiedu, Gladys, Fallon, Elizabeth, Krieger, Janice L.

Mayo Clinic

Cancer Control | October 17, 2024 | Volume: 31 | Issue: No issue available | Pages: No page available

10.1177/10732748241293987 | PMID 39865591 Get It

Objectives Communication barriers, such as channels, comfort, and location, can negatively impact Black prostate cancer survivors’ experiences and health outcomes after treatment. Addressing these barriers promotes a survivor-centric approach that views survivors as active partners in their care. This study explored the communication preferences of Black prostate cancer survivors, focusing on preferred channels, sources, and locations for enhanced quality of life. Design Using grounded theory methodology, we conducted engaged in-depth interviews with 7 Black prostate cancer survivors, centering on their post-treatment experiences. We analyzed participant transcripts to develop codes and themes. Communication accommodation theory (CAT) was applied to examine how survivors adapt their communication styles to navigate barriers and improve their quality of life. CAT helped identify key patterns of survivors’ convergence and divergence in their communication with healthcare providers, crucial for developing survivor-centric communication strategies. Results The analysis revealed the importance of acknowledging cultural and racial perspectives in post-treatment survivorship. Themes extracted from the transcripts included communication barriers, preferences for information channels, and favored locations for sharing information. Survivors expressed a preference for a balance between face-to-face interaction and telehealth, with environments that provide safety and support playing a key role in encouraging vulnerability and open dialogue. Inclusive healthcare practices were seen as essential in empowering Black survivors to engage in meaningful communication without feeling silenced or undervalued, thus fostering a dignified quality of life. Conclusion Tailoring post-treatment communication practices to incorporate cultural sensitivity, inclusive healthcare, and safe spaces is pivotal to supporting Black survivors. These findings provide a pathway to improving survivors’ experiences and empower them to actively shape their survivorship journey. Moreover, they highlight Black men’s need for trustworthy communication with healthcare providers and peers during the post-treatment period, emphasizing the importance of direct, personalized interactions.
Abstract B073: Utilizing Community Living Labs (CoLLab) to address prostate cancer disparities in Black men: An innovative partnership with the American Legion Post and Mayo Clinic
Willis, Floyd B. , Mahin, Collisa, Bolajoko, Opeyemi , Ramirez, Caleb, Pressey, Shannon, Flynn, Shaina, Merriweather, Arnold, Moultrie, Toshiko, Smith, Vermelle, Ford, W. Scott, Green, Derry , Ford, Wayne

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: B073-B073

10.1158/1538-7755.disp24-b073 Get It

Abstract Introduction: Black men experience a significant burden and face greater hurdles in the prevention, detection, treatment, and survival of prostate cancer (CaP). To address barriers and systemic issues associated with CaP, we have established Community Living Lab (CoLLab) Learning Health Systems through a partnership with the American Legion Post (ALP) and Mayo Clinic. The focus is on providing comprehensive prostate health resources, education, amenities, and community health services (REACH). This initiative represents a proactive approach to addressing health disparities in prostate cancer prevention, detection, and treatment to improve CaP health equity for Black men. This study has three primary aims: (1) Co-develop a user-centric CoLLab Learning Health System with collaborating ALPs, (2) Evaluate the impact of the CoLLab Learning Health System using a pretest-posttest design, and (3) Explore the feasibility of replicating the CoLLab Learning Health System in Black communities nationally. Methods: Three ALPs in Northeast Florida are currently included in this pilot study. The study timeline spans 30 months, from October 2023 to March 2026. The target recruitment is 150 Black men aged 30 to 80 years. Community Health Workers (CHWs) are currently recruiting participants to complete the ALP Neighborhood assessment four times over 12 months to measure changes in CaP-related knowledge, attitudes, health beliefs, perceived control, intentions, and cues to action. Participants will be able to access prostate health REACH services at the designated ALPs through education, navigation, and support services. The program will be continuously evaluated for continuous improvement. The reach of the prostate health REACH services, including extent and patterns of use, demographics of participants reached, and successful navigation for social determinants of health (SDOH), clinical trials, and healthcare, will be evaluated. Additionally, participation in the Community Research Registry, indicating interest in being matched with clinical trials at Mayo Clinic, will be assessed. Results: To date, we have trained 10 CHWs for the study who will serve as community navigators to provide REACH services at their designated ALPs. We have had 49 Black men recruited into the study, and they have completed the baseline assessment at various events held at the ALPs. CaP survivors support group, led by ALP, has begun providing survivorship support services, including healthcare navigation, wellness programs, and grocery distribution to Black men and their households in the community surrounding the ALPs. Conclusion: The CoLLab initiative represents a proactive approach to addressing health disparities and improving outcomes for Black men in CaP prevention, detection, treatment, and survivorship. This study represents a crucial step towards eliminating CaP disparities experienced by Black men, contributing to improved health equity and outcomes in this population. Citation Format: Floyd B Willis, Collisa Mahin, Opeyemi O Bolajoko, Caleb Ramirez, Shannon Pressey, Shaina Flynn, Arnold J Merriweather, Toshiko Moultrie, Vermelle Smith, Wayne Ford, Derry Green. Utilizing Community Living Labs (CoLLab) to address prostate cancer disparities in Black men: An innovative partnership with the American Legion Post and Mayo Clinic [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B073.
Abstract B028: Beyond the diagnosis: A town hall event to explore black men’s journey with prostate cancer and sexuality
Kaninjing, Ernie, Ghasemi, Parisa , Danker, Skyler, Morton, Daniel J. , Dwyer, Kathleen , Young, Mary Ellen , Odedina, Folakemi T., Siston, Amy, Cole, Perry , Beckford, Patrick , Reese, Donald , Montgomery, Everett , Odeleye, Roland , Ogunsanya, Motolani E. , Nyame, Yaw A. , Neil, Jordan M. , Alexander, Adam C. , Mitchell, Thomas J. , Kendzor, Darla E.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: B028-B028

10.1158/1538-7755.disp24-b028 Get It

Abstract Introduction Prostate cancer (CaP) significantly impacts Black men, who face higher morbidity despite lower overall mortality. The disease and its treatments profoundly affect sexuality, relationships, and quality of life (QoL), necessitating robust support systems. Healthcare, spousal support, community involvement, and interactions with other survivors are crucial for enhancing survivors' self-esteem and daily functioning. Virtual town halls offer a platform to share trusted information and foster community support, overcoming geographic and structural barriers. This town hall event will explore Black CaP survivors' experiences, focusing on sexuality post-diagnosis and related medical and psychological needs. MethodsOn June 13, 2024, The University of Oklahoma and Stephenson Cancer Center will host the 5th town hall event (via Microsoft Teams) to address Black CaP survivors' sexual health concerns. Previous town halls averaged 70 attendees and covered various aspects of the CaP journey. This event will include storytelling and panel discussions, with presentations from two CaP survivors and their spouses on personal experiences and coping strategies. A urologic oncologist will discuss treatment advancements and early detection, while a clinical health psychologist will address psychological and emotional aspects of survivorship. Simultaneous watch parties will be held in Milledgeville, Georgia, and Dallas, Texas. Interactive Q&A sessions will allow participant engagement. Attendees will complete a post-event survey to assess the session's impact and collect clinical and sociodemographic data. Quantitative data will be analyzed using SPSS v28, and audio-recorded sessions will be transcribed and thematically analyzed using Nvivo. Results will be available by the end of June and presented at the conference. Expected Results Participants will gain a deeper understanding of the intersection between CaP and sexuality in Black men's health. Discussions will highlight the psychological impact of a cancer diagnosis, challenges in maintaining sexual health during and after treatment, and the role of mental health support. The town hall aims to emphasize the importance of a strong support system, providing valuable coping skills through shared experiences and expert insights. Topics will include the emotional and psychological impact of sexual health challenges, partner support, and the necessity of open communication with healthcare providers. The event seeks to improve CaP survivors' QoL by emphasizing continuous education and integrating sexual health into overall survivorship care. Conclusion This town hall event aims to bridge gaps in understanding and addressing Black CaP survivors' sexual health concerns. By fostering open dialogue and providing expert insights, we hope to improve these men's QoL and survivorship care, emphasizing mental health support, spousal support, and continuous education. Citation Format: Motolani Ogunsanya, Ernie Kaninjing, Parisa Ghasemi, Skyler Danker, Daniel Morton, Kathleen Dwyer, Mary Ellen Young, Folakemi T. Odedina, Yaw Nyame, Amy Siston, Jordan Neil, Adam C Alexander, Perry Cole, Patrick Beckford, Donald Reese, Thomas Mitchell, Everett Montgomery, Roland Odeleye, Darla E. Kendzor. Beyond the diagnosis: A town hall event to explore black men’s journey with prostate cancer and sexuality [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B028.
Abstract C042: iCCaRE qualitative interviews for Black prostate cancer survivors and quality of life
Morrison, J. Cayce, Song, Gaole , Bonner, Timethia , Dagne, Getachew , Merriweather, Arnold, Cobran, Ewan K. , Moore, Cassandra N., Bedell, Fornati, Oladapo, Rotimi, Willis, Floyd B. , Oliver, JoAnne S., Kaninjing, Ernie, Dronca, Roxana , Morrison, James, Ashing, Kimlin , McCall, John , Ngufor, Che

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: C042-C042

10.1158/1538-7755.disp24-c042 Get It

Abstract Intro: Compared to white men, Black men bear the highest burden of prostate cancer, experiencing a higher incidence and mortality rate, and poorer survivorship outcomes. Although prioritized, survivorship and quality of life (QOL) are under-studied in the fight against prostate cancer disparities. To address this issue, clinicians, researchers, and community advocates have formed the Inclusive Cancer Care Research Equity (iCCaRE) Consortium for Black Men. iCCaRE’s goal is to advance the science and practice of survivorship focused on the needs of Black men and their loved ones affected by prostate cancer. Methods: We developed a survivorship care plan (SCP) tailored to the whole person's needs. IRB-approved qualitative methods to preliminarily gain evaluation and guidance on the SCP. The SCP presented content in the following areas: diagnosis and treatment, follow-up care/surveillance, family history, care team, major co-morbidities, symptoms and quality of life, survivorship concerns, and health advisories. Results: 23 Black prostate cancer survivors (PCS) participated and provided feedback on the SCP Mean age was 64 years. PCS diagnosed between 2018-2023 between stages 1-4. The Majority of PCS were provided information for follow-up and side effects. But none had received a comprehensive SCP All agreed that the SCP would contribute to enhancing cancer knowledge, patient activation, and shared decision, and their QOL, if the SCP was obtained. A survivor noted “having inspirational quotes throughout the SCP is important”. An unforeseen consequence to the interviews was the emotional release for the men, justifying the need for the SCP and an expansion of its scope. Domains that the men wanted more contents were social support, sexuality, masculinity, and maintaining a healthy lifestyle. All PCS understood the value of having trusted family and friends to bear the burden of the disease despite some not having a solid support system. PCS emphasized the role of family support stating, “my wife and children helped me stay positive”. Another critical lifestyle component that survivors mentioned was their sexuality and how it directly reflects their masculinity. Although PCS adapted to other forms of intimacy like couples’ activities and stronger communication with their partners, majority of men struggle with adapting to their sexual performance. A quote by a survivor encompasses the mindset expressed by many of the men fear “Like a track star in his prime who can’t run anymore”. Erectile Dysfunction can lead to fear and anxiety among survivors, ultimately affecting QOL. Lastly, PCS wanted more options to stay fit and healthy. Further research and resources are needed to address survivor concerns in this area. Discussion: Overall, PCS have acknowledged that the SCP can assist them in these areas of concern, but more research is required. Life after prostate cancer treatment is an ongoing process; while some survivors cope better than others, it is evident a need for more information and guidance is not being provided to all those affected. Citation Format: James Morrison, Kimlin Ashing, Gaole Song, John McCall, Timethia J. Bonner, Che Ngufor, Getachew A. Dagne, Arnold Merriweather, Ewan Cobran, Cassandra N. Moore, Fornati Bedell, Rotimi Oladapo, Floyd B. Willis, JoAnne S. Oliver, Ernie Kaninjing, Roxana Dronca, Folakemi T. Odedina. iCCaRE qualitative interviews for Black prostate cancer survivors and quality of life [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C042.